We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type


Firm name


199 results found


Shook Hardy & Bacon LLP | USA | 10 Jul 2014

Federal court dismisses MDL consumer-fraud claims over GNC dietary supplements

A federal multidistrict litigation (MDL) court in Maryland has dismissed without prejudice the consolidated amended complaint filed by eight named


Wiley Rein LLP | USA | 18 Mar 2014

Insurer required to prove prejudice to deny coverage for late notice under claims-made-and-reported policy

Applying Maryland law, the United States District Court for the District of Maryland has held that an insurer must demonstrate prejudice to support a


Venable LLP | USA | 24 Oct 2013

Maryland trial court upholds Maryland’s narrow futility demand exception and Special Committee’s approval of acquisition of REIT’s external manager

In an opinion issued yesterday, Judge Althea Handy of the Maryland Business and Technology Case Management Program in the Circuit Court for Baltimore


Williams Mullen | USA | 15 Aug 2011

Myung Ga, Inc. v. Myung Ga of Md., Inc..: “formulaic” pleading of trademark and trade dress claims cannot survive Rule 12(b)(6) challenge

On August 8, 2011, the U. S. Court for the District of Maryland granted in part, and denied in part, a motion under Rule 12(b)(6), F.R.C.P., to dismiss claims of trademark and trade dress infringement, trade secret misappropriation and unfair competition


Jones Day | USA | 21 Apr 2011

Former in-house counsel with pharmaceutical company reindicted

On April 13, 2011, a federal grand jury in Maryland returned an indictment charging Lauren Stevens, formerly a vice president and associate general counsel for GlaxoSmithKline (GSK), with obstruction of justice and making false statements to the Food and Drug Administration (FDA) in connection with an investigation into allegations that the drug Wellbutrin had been marketed for unapproved uses.


Kelley Drye & Warren LLP | USA | 5 Apr 2011

In Maryland, insurers cannot rely on self-serving label of ‘condition precedent’ in their insurance policy to deny claim based on late notice

In Sherwood Brands, Inc. v. Great American Ins. Co., No. 62 (Md. Feb. 24, 2011), the Maryland Court of Appeals re-affirmed Maryland's long-standing public policy - embraced by both the courts and the legislature since 1964 - that an insurer cannot deny coverage based on late notice, unless the insurer can prove that it was prejudiced.


Faegre Baker Daniels LLP | USA | 31 Mar 2011

Judge dismisses without prejudice bellwether indictment of GSK attorney

As previously reported, media and legal analysts speculated that the November 8, 2010 indictment of former GlaxoSmithKline vice-president and associate general counsel Lauren Stevens would have a chilling effect on the lawyers and executives in the pharmaceutical industry.


Venable LLP | USA | 30 Mar 2011

Indictment of former GSK lawyer dismissed

On March 23, 2011, United States District Judge Roger Titus in Greenbelt, Maryland dismissed the indictment of former GlaxoSmithKline in-house counsel Lauren Stevens because prosecutors erroneously instructed the grand jury that the advice of counsel defense did not apply until trial.


Baker Donelson Bearman Caldwell & Berkowitz PC | USA | 29 Mar 2011

Advice of counsel shield upheld -- for now

On March 23, 2011, the United States District Court for the District of Maryland dismissed without prejudice the prosecution of Lauren Stevens, former GlaxoSmithKline Vice President and Associate General Counsel.


Kelley Drye & Warren LLP | USA | 24 Mar 2011

Breaking news: court dismisses indictment against former GSK attorney

Yesterday, a federal district court for the District of Maryland issued an opinion dismissing without prejudice the indictment against former GSK in-house attorney Lauren Stevens accusing her of obstruction and making false statements in connection with an FDA inquiry concerning the company's marketing practices for Wellbutrin.

Previous page 1 2 3 ...